Roadmap for the next generation of Children's Oncology Group rhabdomyosarcoma trials

Area of Science:

• Pediatric Oncology
• Rhabdomyosarcoma Research
• Clinical Trial Design

Background:

• Past clinical trials by the Intergroup Rhabdomyosarcoma Study Group and Children's Oncology Group have set current RMS diagnostic and therapeutic standards.
• Advances in RMS biology and clinical behavior necessitate more refined approaches to diagnosis, risk stratification, and treatment.
• The rarity of RMS and treatment complexities challenge large-scale clinical trials for new therapeutic strategies.

Purpose of the Study:

• To outline a strategic plan for the next generation of rhabdomyosarcoma (RMS) clinical trials.
• To address critical questions in RMS treatment, including novel agent efficacy, biomarkers, toxicity, and quality of life.
• To propose a framework for future RMS research based on five key themes.

Main Methods:

• Systematic planning of future clinical trials in rhabdomyosarcoma (RMS).
• Focus on five strategic themes for next-generation trials: novel agent identification and translation, efficient trial development, knowledge generation, toxicity reduction, and patient engagement.
• Leveraging insights from the Children's Oncology Group Soft Tissue Sarcoma Committee.

Main Results:

• A proposed strategic approach for future RMS clinical trials is outlined.
• The plan emphasizes five key areas to advance RMS treatment and research.
• Focus on improving novel agent translation, trial efficiency, knowledge generation, toxicity management, and patient engagement.

Conclusions:

• Strategic planning is crucial for future RMS clinical trials due to treatment complexities and disease rarity.
• The proposed five-theme approach by the Children's Oncology Group aims to optimize future RMS research.
• Future trials must address novel therapies, biomarkers, toxicity, and patient quality of life for improved outcomes.